data_1sf0_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1sf0 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 121.27 0.557 . . . . 0.0 109.512 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . . . -125.23 153.85 42.52 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.325 -0.859 . . . . 0.0 109.511 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . . . -133.18 154.34 39.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.327 -0.858 . . . . 0.0 109.57 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.722 ' O ' ' N ' ' A' ' 60' ' ' VAL . . . -116.92 123.57 47.32 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.26 -0.9 . . . . 0.0 109.152 179.737 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.418 ' HA ' ' CB ' ' A' ' 60' ' ' VAL . . . -100.15 137.91 26.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.212 -0.93 . . . . 0.0 110.061 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . . . -146.02 150.3 35.73 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.315 -0.866 . . . . 0.0 109.139 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.424 ' O ' ' C ' ' A' ' 9' ' ' ILE . . . -89.98 149.58 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.081 -1.012 . . . . 0.0 109.483 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.424 ' C ' ' O ' ' A' ' 8' ' ' VAL . . . -43.85 112.8 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.215 -0.928 . . . . 0.0 109.627 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 63.63 42.5 98.75 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.988 -1.245 . . . . 0.0 109.988 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.564 ' O ' ' CB ' ' A' ' 12' ' ' ASN . . . -101.98 -25.65 13.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.121 -1.223 . . . . 0.0 109.438 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . 0.564 ' CB ' ' O ' ' A' ' 11' ' ' ARG . . . 79.65 57.32 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.33 -0.856 . . . . 0.0 109.544 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . . . -120.15 96.91 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.146 -0.971 . . . . 0.0 109.78 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . . . -102.15 130.23 48.72 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.46 -0.775 . . . . 0.0 109.205 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.552 ' O ' ' C ' ' A' ' 16' ' ' GLU . . . -152.58 90.4 1.48 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.22 -0.925 . . . . 0.0 109.456 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . 0.552 ' C ' ' O ' ' A' ' 15' ' ' LYS . . . -36.43 156.77 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.037 -1.04 . . . . 0.0 109.152 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . . . -149.0 139.06 16.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.165 -0.959 . . . . 0.0 110.018 -179.439 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . . . -72.02 -133.49 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.279 -0.888 . . . . 0.0 109.516 179.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . . . -177.33 172.75 1.83 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.365 -0.834 . . . . 0.0 109.148 179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . 0.608 ' O ' ' CB ' ' A' ' 21' ' ' GLU . . . -140.65 -91.88 0.16 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.068 -1.02 . . . . 0.0 109.862 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.608 ' CB ' ' O ' ' A' ' 20' ' ' ARG . . . 157.74 118.9 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.051 -1.031 . . . . 0.0 109.56 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 110.09 -27.81 11.29 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . . . -59.11 -167.6 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.283 -1.128 . . . . 0.0 109.68 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . 0.554 ' O ' ' C ' ' A' ' 25' ' ' VAL . . . -173.39 141.33 0.89 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.4 -0.813 . . . . 0.0 109.564 -179.39 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.554 ' C ' ' O ' ' A' ' 24' ' ' LYS . . . -32.91 -55.05 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.324 -0.86 . . . . 0.0 109.813 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.618 ' CB ' ' O ' ' A' ' 50' ' ' GLU . . . -48.36 -67.65 0.25 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.158 -0.964 . . . . 0.0 109.181 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.486 ' C ' ' O ' ' A' ' 26' ' ' ARG . . . -39.53 -65.19 0.41 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.184 -0.948 . . . . 0.0 109.303 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.4 ' C ' ' O ' ' A' ' 27' ' ' ASP . . . -45.13 -44.42 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.24 -0.913 . . . . 0.0 109.418 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . . . -65.67 -53.01 47.08 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.233 -0.917 . . . . 0.0 109.179 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . . . -60.15 -12.88 9.62 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.283 -0.886 . . . . 0.0 109.389 179.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -74.36 -15.51 60.94 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.255 -0.903 . . . . 0.0 109.454 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . . . -108.98 18.36 6.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.271 -0.893 . . . . 0.0 108.944 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 70.56 20.08 76.87 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . . . -150.17 100.74 2.94 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.301 -1.117 . . . . 0.0 109.647 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . . . -77.73 47.68 0.63 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.158 -0.964 . . . . 0.0 109.336 179.708 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . . . 60.35 57.64 2.81 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.402 -0.811 . . . . 0.0 109.782 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . . . -100.09 -37.16 9.08 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.207 -0.933 . . . . 0.0 109.227 179.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.633 ' O ' ' CB ' ' A' ' 39' ' ' ALA . . . -98.32 55.97 1.15 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.619 -0.676 . . . . 0.0 109.65 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.633 ' CB ' ' O ' ' A' ' 38' ' ' SER . . . 154.9 158.42 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.126 -0.983 . . . . 0.0 110.016 -179.599 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . . . -92.7 103.86 15.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -54.69 130.62 41.13 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.048 -1.033 . . . . 0.0 109.606 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . . . -150.22 140.36 22.12 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.297 -0.877 . . . . 0.0 109.392 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . . . -128.15 149.57 33.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.171 -0.956 . . . . 0.0 109.769 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . . . 52.91 34.26 16.32 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.389 -0.819 . . . . 0.0 109.918 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 74.98 -4.75 36.56 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 110.046 -1.221 . . . . 0.0 110.046 179.59 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . . . -98.68 142.4 30.29 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.211 -1.17 . . . . 0.0 109.443 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . . . -91.11 155.5 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.366 -0.834 . . . . 0.0 109.697 -179.756 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . . . -150.09 178.86 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.412 -0.805 . . . . 0.0 109.297 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . . . -101.73 169.36 8.86 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.166 -0.959 . . . . 0.0 109.36 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.618 ' O ' ' CB ' ' A' ' 26' ' ' ARG . . . -60.27 -26.1 66.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.216 -0.927 . . . . 0.0 109.557 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . . . -95.47 4.06 53.63 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.261 -0.899 . . . . 0.0 109.757 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.493 ' O ' ' C ' ' A' ' 53' ' ' GLU . . . -77.99 99.07 5.92 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.188 -0.945 . . . . 0.0 109.237 179.909 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.493 ' C ' ' O ' ' A' ' 52' ' ' ASP . . . -39.2 156.18 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.286 -0.884 . . . . 0.0 109.635 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.463 ' N ' ' H ' ' A' ' 25' ' ' VAL . . . -124.93 160.47 30.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -0.878 . . . . 0.0 109.044 179.674 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.684 ' O ' ' N ' ' A' ' 57' ' ' GLY . . . -149.2 -149.87 0.32 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.21 -0.931 . . . . 0.0 109.535 -179.71 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.55 ' C ' ' O ' ' A' ' 55' ' ' LYS . . . 31.4 30.77 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.539 -0.726 . . . . 0.0 109.917 179.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.684 ' N ' ' O ' ' A' ' 55' ' ' LYS . . . 57.83 69.58 1.24 Allowed Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.289 -1.524 . . . . 0.0 109.289 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . . . -67.09 155.8 37.76 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.265 -1.139 . . . . 0.0 109.061 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . 0.605 ' CA ' ' O ' ' A' ' 5' ' ' LYS . . . -81.81 -148.94 0.07 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.125 -0.984 . . . . 0.0 109.425 -179.549 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.722 ' N ' ' O ' ' A' ' 5' ' ' LYS . . . -150.12 93.98 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 179.544 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . . . -85.84 124.38 32.26 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.12 -0.987 . . . . 0.0 110.038 -179.369 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.658 ' O ' ' CB ' ' A' ' 63' ' ' ILE . . . -142.83 105.79 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.392 -0.817 . . . . 0.0 109.445 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.658 ' CB ' ' O ' ' A' ' 62' ' ' VAL . . . 152.29 149.3 0.0 OUTLIER Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.484 -0.76 . . . . 0.0 109.366 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . . . -41.16 84.87 0.01 OUTLIER 'Trans proline' 0 C--N 1.306 -1.691 0 C-N-CA 122.971 2.447 . . . . 0.0 112.53 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.494 ' N ' ' O ' ' A' ' 63' ' ' ILE . . . -92.48 31.51 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.192 -0.943 . . . . 0.0 109.138 179.664 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . . . -88.66 169.98 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.417 -0.802 . . . . 0.0 109.538 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . . . -174.2 139.86 0.65 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.251 -0.906 . . . . 0.0 109.405 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -115.35 99.6 0.91 Allowed Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.317 0 CA-C-O 118.013 -1.437 . . . . 0.0 109.563 179.972 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 121.27 0.557 . . . . 0.0 109.512 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . . . -125.23 153.85 42.52 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.325 -0.859 . . . . 0.0 109.511 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . . . -133.18 154.34 39.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.327 -0.858 . . . . 0.0 109.57 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.722 ' O ' ' N ' ' A' ' 60' ' ' VAL . . . -116.92 123.57 47.32 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.26 -0.9 . . . . 0.0 109.152 179.737 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.418 ' HA ' ' CB ' ' A' ' 60' ' ' VAL . . . -100.15 137.91 26.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.212 -0.93 . . . . 0.0 110.061 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . . . -146.02 150.3 35.73 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.315 -0.866 . . . . 0.0 109.139 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.424 ' O ' ' C ' ' A' ' 9' ' ' ILE . . . -89.98 149.58 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.081 -1.012 . . . . 0.0 109.483 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.424 ' C ' ' O ' ' A' ' 8' ' ' VAL . . . -43.85 112.8 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.215 -0.928 . . . . 0.0 109.627 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 63.63 42.5 98.75 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.988 -1.245 . . . . 0.0 109.988 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.564 ' O ' ' CB ' ' A' ' 12' ' ' ASN . . . -101.98 -25.65 13.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.121 -1.223 . . . . 0.0 109.438 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ASN . . . . . 0.564 ' CB ' ' O ' ' A' ' 11' ' ' ARG . . . 79.65 57.32 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.33 -0.856 . . . . 0.0 109.544 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . . . -120.15 96.91 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.146 -0.971 . . . . 0.0 109.78 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . . . -102.15 130.23 48.72 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.46 -0.775 . . . . 0.0 109.205 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.552 ' O ' ' C ' ' A' ' 16' ' ' GLU . . . -152.58 90.4 1.48 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.22 -0.925 . . . . 0.0 109.456 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLU . . . . . 0.552 ' C ' ' O ' ' A' ' 15' ' ' LYS . . . -36.43 156.77 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.037 -1.04 . . . . 0.0 109.152 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . . . -149.0 139.06 16.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.165 -0.959 . . . . 0.0 110.018 -179.439 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . . . -72.02 -133.49 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.279 -0.888 . . . . 0.0 109.516 179.712 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . . . -177.33 172.75 1.83 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.365 -0.834 . . . . 0.0 109.148 179.901 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ARG . . . . . 0.608 ' O ' ' CB ' ' A' ' 21' ' ' GLU . . . -140.65 -91.88 0.16 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.068 -1.02 . . . . 0.0 109.862 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.608 ' CB ' ' O ' ' A' ' 20' ' ' ARG . . . 157.74 118.9 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.051 -1.031 . . . . 0.0 109.56 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 110.09 -27.81 11.29 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . . . -59.11 -167.6 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.283 -1.128 . . . . 0.0 109.68 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' LYS . . . . . 0.554 ' O ' ' C ' ' A' ' 25' ' ' VAL . . . -173.39 141.33 0.89 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.4 -0.813 . . . . 0.0 109.564 -179.39 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.554 ' C ' ' O ' ' A' ' 24' ' ' LYS . . . -32.91 -55.05 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.324 -0.86 . . . . 0.0 109.813 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.618 ' CB ' ' O ' ' A' ' 50' ' ' GLU . . . -48.36 -67.65 0.25 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.158 -0.964 . . . . 0.0 109.181 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.486 ' C ' ' O ' ' A' ' 26' ' ' ARG . . . -39.53 -65.19 0.41 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.184 -0.948 . . . . 0.0 109.303 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.438 ' O ' ' HB3' ' A' ' 31' ' ' ALA . . . -45.13 -44.42 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.24 -0.913 . . . . 0.0 109.418 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . . . -65.67 -53.01 47.08 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.233 -0.917 . . . . 0.0 109.179 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . . . -60.15 -12.88 9.62 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.283 -0.886 . . . . 0.0 109.389 179.684 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' A' ' 28' ' ' ILE . . . -74.36 -15.51 60.94 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.255 -0.903 . . . . 0.0 109.454 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . . . -108.98 18.36 6.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.271 -0.893 . . . . 0.0 108.944 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 70.56 20.08 76.87 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . . . -150.17 100.74 2.94 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.301 -1.117 . . . . 0.0 109.647 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . . . -77.73 47.68 0.63 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.158 -0.964 . . . . 0.0 109.336 179.708 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . . . 60.35 57.64 2.81 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.402 -0.811 . . . . 0.0 109.782 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . . . -100.09 -37.16 9.08 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.207 -0.933 . . . . 0.0 109.227 179.688 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.815 ' O ' ' HB2' ' A' ' 39' ' ' ALA . . . -98.32 55.97 1.15 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.619 -0.676 . . . . 0.0 109.65 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.815 ' HB2' ' O ' ' A' ' 38' ' ' SER . . . 154.9 158.42 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.126 -0.983 . . . . 0.0 110.016 -179.599 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . . . -92.7 103.86 15.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.58 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -54.69 130.62 41.13 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.048 -1.033 . . . . 0.0 109.606 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . . . -150.22 140.36 22.12 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.297 -0.877 . . . . 0.0 109.392 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . . . -128.15 149.57 33.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.171 -0.956 . . . . 0.0 109.769 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . . . 52.91 34.26 16.32 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.389 -0.819 . . . . 0.0 109.918 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 74.98 -4.75 36.56 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 110.046 -1.221 . . . . 0.0 110.046 179.59 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . . . -98.68 142.4 30.29 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.211 -1.17 . . . . 0.0 109.443 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . . . -91.11 155.5 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.366 -0.834 . . . . 0.0 109.697 -179.756 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . . . -150.09 178.86 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.412 -0.805 . . . . 0.0 109.297 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . . . -101.73 169.36 8.86 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.166 -0.959 . . . . 0.0 109.36 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.618 ' O ' ' CB ' ' A' ' 26' ' ' ARG . . . -60.27 -26.1 66.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.216 -0.927 . . . . 0.0 109.557 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . . . -95.47 4.06 53.63 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.261 -0.899 . . . . 0.0 109.757 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.493 ' O ' ' C ' ' A' ' 53' ' ' GLU . . . -77.99 99.07 5.92 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.188 -0.945 . . . . 0.0 109.237 179.909 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.493 ' C ' ' O ' ' A' ' 52' ' ' ASP . . . -39.2 156.18 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.286 -0.884 . . . . 0.0 109.635 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.504 ' N ' ' H ' ' A' ' 25' ' ' VAL . . . -124.93 160.47 30.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -0.878 . . . . 0.0 109.044 179.674 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.684 ' O ' ' N ' ' A' ' 57' ' ' GLY . . . -149.2 -149.87 0.32 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.21 -0.931 . . . . 0.0 109.535 -179.71 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.55 ' C ' ' O ' ' A' ' 55' ' ' LYS . . . 31.4 30.77 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.539 -0.726 . . . . 0.0 109.917 179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.684 ' N ' ' O ' ' A' ' 55' ' ' LYS . . . 57.83 69.58 1.24 Allowed Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.289 -1.524 . . . . 0.0 109.289 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . . . -67.09 155.8 37.76 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.265 -1.139 . . . . 0.0 109.061 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' PHE . . . . . 0.605 ' CA ' ' O ' ' A' ' 5' ' ' LYS . . . -81.81 -148.94 0.07 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.125 -0.984 . . . . 0.0 109.425 -179.549 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.722 ' N ' ' O ' ' A' ' 5' ' ' LYS . . . -150.12 93.98 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 179.544 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . . . -85.84 124.38 32.26 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.12 -0.987 . . . . 0.0 110.038 -179.369 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.658 ' O ' ' CB ' ' A' ' 63' ' ' ILE . . . -142.83 105.79 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.392 -0.817 . . . . 0.0 109.445 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.658 ' CB ' ' O ' ' A' ' 62' ' ' VAL . . . 152.29 149.3 0.0 OUTLIER Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.484 -0.76 . . . . 0.0 109.366 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . . . -41.16 84.87 0.01 OUTLIER 'Trans proline' 0 C--N 1.306 -1.691 0 C-N-CA 122.971 2.447 . . . . 0.0 112.53 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.494 ' N ' ' O ' ' A' ' 63' ' ' ILE . . . -92.48 31.51 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.192 -0.943 . . . . 0.0 109.138 179.664 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . . . -88.66 169.98 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.417 -0.802 . . . . 0.0 109.538 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . . . -174.2 139.86 0.65 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.251 -0.906 . . . . 0.0 109.405 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -115.35 99.6 0.91 Allowed Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.317 0 CA-C-O 118.013 -1.437 . . . . 0.0 109.563 179.972 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.537 0 CA-C-O 121.27 0.557 . . . . 0.0 109.512 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . . . -125.23 153.85 42.52 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.325 -0.859 . . . . 0.0 109.511 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . . . -133.18 154.34 39.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.327 -0.858 . . . . 0.0 109.57 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.722 ' O ' ' N ' ' A' ' 60' ' ' VAL . . . -116.92 123.57 47.32 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.26 -0.9 . . . . 0.0 109.152 179.737 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.418 ' HA ' ' CB ' ' A' ' 60' ' ' VAL . . . -100.15 137.91 26.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.212 -0.93 . . . . 0.0 110.061 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . . . -146.02 150.3 35.73 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.315 -0.866 . . . . 0.0 109.139 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.424 ' O ' ' C ' ' A' ' 9' ' ' ILE . . . -89.98 149.58 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.081 -1.012 . . . . 0.0 109.483 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.424 ' C ' ' O ' ' A' ' 8' ' ' VAL . . . -43.85 112.8 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.215 -0.928 . . . . 0.0 109.627 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 63.63 42.5 98.75 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.988 -1.245 . . . . 0.0 109.988 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.564 ' O ' ' CB ' ' A' ' 12' ' ' ASN . . . -101.98 -25.65 13.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.121 -1.223 . . . . 0.0 109.438 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . 0.564 ' CB ' ' O ' ' A' ' 11' ' ' ARG . . . 79.65 57.32 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.33 -0.856 . . . . 0.0 109.544 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . . . -120.15 96.91 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.146 -0.971 . . . . 0.0 109.78 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . . . -102.15 130.23 48.72 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.46 -0.775 . . . . 0.0 109.205 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.552 ' O ' ' C ' ' A' ' 16' ' ' GLU . . . -152.58 90.4 1.48 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.22 -0.925 . . . . 0.0 109.456 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . 0.552 ' C ' ' O ' ' A' ' 15' ' ' LYS . . . -36.43 156.77 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.037 -1.04 . . . . 0.0 109.152 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . . . -149.0 139.06 16.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.165 -0.959 . . . . 0.0 110.018 -179.439 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . . . -72.02 -133.49 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.279 -0.888 . . . . 0.0 109.516 179.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . . . -177.33 172.75 1.83 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.365 -0.834 . . . . 0.0 109.148 179.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . 0.608 ' O ' ' CB ' ' A' ' 21' ' ' GLU . . . -140.65 -91.88 0.16 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.068 -1.02 . . . . 0.0 109.862 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.608 ' CB ' ' O ' ' A' ' 20' ' ' ARG . . . 157.74 118.9 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.051 -1.031 . . . . 0.0 109.56 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 110.09 -27.81 11.29 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . . . -59.11 -167.6 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.283 -1.128 . . . . 0.0 109.68 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . 0.554 ' O ' ' C ' ' A' ' 25' ' ' VAL . . . -173.39 141.33 0.89 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.4 -0.813 . . . . 0.0 109.564 -179.39 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.554 ' C ' ' O ' ' A' ' 24' ' ' LYS . . . -32.91 -55.05 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.324 -0.86 . . . . 0.0 109.813 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.618 ' CB ' ' O ' ' A' ' 50' ' ' GLU . . . -48.36 -67.65 0.25 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.158 -0.964 . . . . 0.0 109.181 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.486 ' C ' ' O ' ' A' ' 26' ' ' ARG . . . -39.53 -65.19 0.41 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.184 -0.948 . . . . 0.0 109.303 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.438 ' O ' ' HB3' ' A' ' 31' ' ' ALA . . . -45.13 -44.42 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.24 -0.913 . . . . 0.0 109.418 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . . . -65.67 -53.01 47.08 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.233 -0.917 . . . . 0.0 109.179 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . . . -60.15 -12.88 9.62 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.283 -0.886 . . . . 0.0 109.389 179.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' A' ' 28' ' ' ILE . . . -74.36 -15.51 60.94 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.255 -0.903 . . . . 0.0 109.454 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . . . -108.98 18.36 6.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.271 -0.893 . . . . 0.0 108.944 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 70.56 20.08 76.87 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . . . -150.17 100.74 2.94 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.301 -1.117 . . . . 0.0 109.647 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . . . -77.73 47.68 0.63 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.158 -0.964 . . . . 0.0 109.336 179.708 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . . . 60.35 57.64 2.81 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.402 -0.811 . . . . 0.0 109.782 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . . . -100.09 -37.16 9.08 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.207 -0.933 . . . . 0.0 109.227 179.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.815 ' O ' ' HB2' ' A' ' 39' ' ' ALA . . . -98.32 55.97 1.15 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.619 -0.676 . . . . 0.0 109.65 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.815 ' HB2' ' O ' ' A' ' 38' ' ' SER . . . 154.9 158.42 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.126 -0.983 . . . . 0.0 110.016 -179.599 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . . . -92.7 103.86 15.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -54.69 130.62 41.13 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.048 -1.033 . . . . 0.0 109.606 -179.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . . . . . . . . . . . -150.22 140.36 22.12 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.297 -0.877 . . . . 0.0 109.392 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . . . -128.15 149.57 33.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.171 -0.956 . . . . 0.0 109.769 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . . . 52.91 34.26 16.32 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.389 -0.819 . . . . 0.0 109.918 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 74.98 -4.75 36.56 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 110.046 -1.221 . . . . 0.0 110.046 179.59 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . . . -98.68 142.4 30.29 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.211 -1.17 . . . . 0.0 109.443 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . . . -91.11 155.5 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.366 -0.834 . . . . 0.0 109.697 -179.756 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . . . -150.09 178.86 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.412 -0.805 . . . . 0.0 109.297 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . . . -101.73 169.36 8.86 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.166 -0.959 . . . . 0.0 109.36 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.618 ' O ' ' CB ' ' A' ' 26' ' ' ARG . . . -60.27 -26.1 66.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.216 -0.927 . . . . 0.0 109.557 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . . . -95.47 4.06 53.63 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.261 -0.899 . . . . 0.0 109.757 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.493 ' O ' ' C ' ' A' ' 53' ' ' GLU . . . -77.99 99.07 5.92 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.188 -0.945 . . . . 0.0 109.237 179.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.493 ' C ' ' O ' ' A' ' 52' ' ' ASP . . . -39.2 156.18 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.286 -0.884 . . . . 0.0 109.635 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.504 ' N ' ' H ' ' A' ' 25' ' ' VAL . . . -124.93 160.47 30.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -0.878 . . . . 0.0 109.044 179.674 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.684 ' O ' ' N ' ' A' ' 57' ' ' GLY . . . -149.2 -149.87 0.32 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.21 -0.931 . . . . 0.0 109.535 -179.71 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.55 ' C ' ' O ' ' A' ' 55' ' ' LYS . . . 31.4 30.77 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.539 -0.726 . . . . 0.0 109.917 179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.684 ' N ' ' O ' ' A' ' 55' ' ' LYS . . . 57.83 69.58 1.24 Allowed Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.289 -1.524 . . . . 0.0 109.289 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . . . -67.09 155.8 37.76 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.265 -1.139 . . . . 0.0 109.061 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . 0.605 ' CA ' ' O ' ' A' ' 5' ' ' LYS . . . -81.81 -148.94 0.07 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.125 -0.984 . . . . 0.0 109.425 -179.549 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.722 ' N ' ' O ' ' A' ' 5' ' ' LYS . . . -150.12 93.98 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 179.544 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . . . -85.84 124.38 32.26 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.12 -0.987 . . . . 0.0 110.038 -179.369 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.658 ' O ' ' CB ' ' A' ' 63' ' ' ILE . . . -142.83 105.79 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.392 -0.817 . . . . 0.0 109.445 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.658 ' CB ' ' O ' ' A' ' 62' ' ' VAL . . . 152.29 149.3 0.0 OUTLIER Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.484 -0.76 . . . . 0.0 109.366 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . . . . . . . . . . . -41.16 84.87 0.01 OUTLIER 'Trans proline' 0 C--N 1.306 -1.691 0 C-N-CA 122.971 2.447 . . . . 0.0 112.53 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.494 ' N ' ' O ' ' A' ' 63' ' ' ILE . . . -92.48 31.51 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.192 -0.943 . . . . 0.0 109.138 179.664 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . . . -88.66 169.98 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.417 -0.802 . . . . 0.0 109.538 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . . . -174.2 139.86 0.65 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.251 -0.906 . . . . 0.0 109.405 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -115.35 99.6 0.91 Allowed Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.317 0 CA-C-O 118.013 -1.437 . . . . 0.0 109.563 179.972 . . . . . . . . 0 0 . 1 stop_ save_